Government
Every published round New South Wales Department of Health and Medical Research took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies New South Wales Department of Health and Medical Research has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for New South Wales Department of Health and Medical Research, as distinct from the investments it has made.
Companies New South Wales Department of Health and Medical Research has backed that another company then bought. An exit for the holding, not a deal New South Wales Department of Health and Medical Research did.
Stories naming New South Wales Department of Health and Medical Research. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.